中文版 | English
题名

FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature

作者
通讯作者Xie, Li
发表日期
2022-04-01
DOI
发表期刊
ISSN
0278-0240
EISSN
1875-8630
卷号2022
摘要
Background. Pyroptosis is a form of programmed cell death, playing a significant role in cancer. Glioblastoma multiforme (GBM) is the most common malignant brain tumor. The poor prognosis in GBM due to temozolomide (TMZ) resistance has been widely discussed. Such being the case, the correlation between TMZ resistance and pyroptosis is seldom investigated. On this basis, this paper aims to explore the potential prognostic value of genes related to TMZ resistance and pyroptosis as well as their relationship to the immune microenvironment in GBM. Methods. A total of 103 patients from TCGA were assigned to a training cohort; 190 from CGGA were assigned to a validation cohort. The prognostic risk model reflecting pyroptosis and TMZ resistance was built from the training cohort using multivariate Cox regression and performed validation. RT-qPCR was used to examine the expression of 4 genes from the risk signature. FOXP3 was selected for overexpression and verified using the western blot. The TMZ IC50 of FOXP3-overexpressed cell lines was determined by CCK8. Results. A four genes-based risk signature was established and validated, separating GBM patients into high- and low-risk groups. Compared with the low-risk group, the high-risk group presented worse clinical survival outcomes. Its differential expressed genes were enriched in immune-related pathways and closely related to the immune microenvironment. Moreover, RT-qPCR results suggested that FOXP3, IRF3, and CD274 were significantly upregulated in TMZ-resistant strains, while TP63 was downregulated. FOXP3-overexpressed GBM cell lines had higher TMZ IC50, implying an increased resistance of TMZ. Conclusion. A novel gene signature relevant to pyroptosis and TMZ resistance was constructed and could be used for the prognosis of GBM. The four genes from the risk model might play a potential role in antitumor immunity and serve as therapeutic targets for GBM.
相关链接[来源记录]
收录类别
语种
英语
学校署名
其他
资助项目
National Natural Science Foundation of China[81802658] ; Scientific Research Program of Hunan Provincial Health Commission[202208024824,20200763] ; Basic Research Project of Changsha Science and Technology Bureau[kq2004127]
WOS研究方向
Biotechnology & Applied Microbiology ; Genetics & Heredity ; Research & Experimental Medicine ; Pathology
WOS类目
Biotechnology & Applied Microbiology ; Genetics & Heredity ; Medicine, Research & Experimental ; Pathology
WOS记录号
WOS:000820187000001
出版者
ESI学科分类
CLINICAL MEDICINE
来源库
Web of Science
引用统计
被引频次[WOS]:7
成果类型期刊论文
条目标识符http://sustech.caswiz.com/handle/2SGJ60CL/353386
专题南方科技大学第一附属医院
作者单位
1.Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Dept Head & Neck Surg, Changsha 410013, Hunan, Peoples R China
2.Hunan Normal Univ, Sch Med, Changsha 410013, Hunan, Peoples R China
3.Southern Univ Sci & Technol, Dept Pathol, Clin Med Coll 2, Jinan Univ,Affiliated Hosp 1, Shenzhen 518020, Peoples R China
推荐引用方式
GB/T 7714
Liang, Lu,Yan, Bin,Liu, Yueying,et al. FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature[J]. DISEASE MARKERS,2022,2022.
APA
Liang, Lu.,Yan, Bin.,Liu, Yueying.,Jiang, Shiyao.,He, Hua.,...&Xie, Li.(2022).FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature.DISEASE MARKERS,2022.
MLA
Liang, Lu,et al."FOXP3 Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature".DISEASE MARKERS 2022(2022).
条目包含的文件
条目无相关文件。
个性服务
原文链接
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
导出为Excel格式
导出为Csv格式
Altmetrics Score
谷歌学术
谷歌学术中相似的文章
[Liang, Lu]的文章
[Yan, Bin]的文章
[Liu, Yueying]的文章
百度学术
百度学术中相似的文章
[Liang, Lu]的文章
[Yan, Bin]的文章
[Liu, Yueying]的文章
必应学术
必应学术中相似的文章
[Liang, Lu]的文章
[Yan, Bin]的文章
[Liu, Yueying]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
[发表评论/异议/意见]
暂无评论

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。